About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Expert Opinion on Emerging Drugs
›
top-articles
Expert Opinion on Emerging Drugs
2.9
(top 20%)
impact factor
788
(top 20%)
papers
16.3K
(top 10%)
citations
53
(top 10%)
h
-index
3.2
(top 20%)
impact factor
935
all documents
17.0K
doc citations
78
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Emerging PEGylated drugs
Expert Opinion on Emerging Drugs
2009
226
2
What is the future of PEGylated therapies?
Expert Opinion on Emerging Drugs
2015
193
3
Emerging treatments for traumatic brain injury
Expert Opinion on Emerging Drugs
2009
180
4
Transgenic plants in the biopharmaceutical market
Expert Opinion on Emerging Drugs
2005
172
5
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity
Expert Opinion on Emerging Drugs
2008
165
6
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis
Expert Opinion on Emerging Drugs
2009
161
7
Emerging treatments for noise-induced hearing loss
Expert Opinion on Emerging Drugs
2011
148
8
Emerging anti-HIV drugs
Expert Opinion on Emerging Drugs
2005
137
9
Liposomal amphotericin B as a treatment for human leishmaniasis
Expert Opinion on Emerging Drugs
2012
130
10
Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update
Expert Opinion on Emerging Drugs
2005
127
11
Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics
Expert Opinion on Emerging Drugs
2018
119
12
Adenosine receptor agonists: from basic medicinal chemistry to clinical development
Expert Opinion on Emerging Drugs
2003
117
13
Current and emerging pharmacotherapies for treating tobacco dependence
Expert Opinion on Emerging Drugs
2006
110
14
Emerging pharmacotherapy of tinnitus
Expert Opinion on Emerging Drugs
2009
104
15
Emerging drugs for the treatment of anxiety
Expert Opinion on Emerging Drugs
2015
102
16
Emerging adenosine receptor agonists
Expert Opinion on Emerging Drugs
2007
100
17
Emerging drugs to treat squamous cell carcinomas of the head and neck
Expert Opinion on Emerging Drugs
2010
96
18
Emerging drugs for high-grade osteosarcoma
Expert Opinion on Emerging Drugs
2010
92
19
Emerging Bcl-2 inhibitors for the treatment of cancer
Expert Opinion on Emerging Drugs
2011
92
20
Emerging pharmacological strategies in the fight against cocaine addiction
Expert Opinion on Emerging Drugs
2006
91
21
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis
Expert Opinion on Emerging Drugs
2006
91
22
Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents
Expert Opinion on Emerging Drugs
2002
88
23
Emerging drugs for Duchenne muscular dystrophy
Expert Opinion on Emerging Drugs
2012
87
24
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
Expert Opinion on Emerging Drugs
2008
84
25
Emerging drugs for uveitis
Expert Opinion on Emerging Drugs
2011
83
26
Advances in pharmacotherapy for tobacco dependence
Expert Opinion on Emerging Drugs
2004
82
27
Advances in ischemic stroke treatment: neuroprotective and combination therapies
Expert Opinion on Emerging Drugs
2007
82
28
Emerging drugs for osteoarthritis
Expert Opinion on Emerging Drugs
2011
82
29
Emerging medication for the treatment of male hypogonadism
Expert Opinion on Emerging Drugs
2012
82
30
Advances in emerging drugs for osteosarcoma
Expert Opinion on Emerging Drugs
2015
82
31
Developments in the treatment of visceral leishmaniasis
Expert Opinion on Emerging Drugs
2009
79
32
Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors
Expert Opinion on Emerging Drugs
2004
78
33
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity
Expert Opinion on Emerging Drugs
2012
75
34
The future is today: emerging drugs for the treatment of erectile dysfunction
Expert Opinion on Emerging Drugs
2010
74
35
Emerging drugs for major depressive disorder
Expert Opinion on Emerging Drugs
2012
74
36
Histone modification enzymes: novel targets for cancer drugs
Expert Opinion on Emerging Drugs
2004
70
37
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration
Expert Opinion on Emerging Drugs
2017
70
38
Therapeutic options to target angiogenesis in human malignancies
Expert Opinion on Emerging Drugs
2006
68
39
Drugs in the medical treatment of Cushing's syndrome
Expert Opinion on Emerging Drugs
2009
68
40
“Is there an emerging need for new antifungals?”
Expert Opinion on Emerging Drugs
2016
68
41
Emerging drugs in neuropathic pain
Expert Opinion on Emerging Drugs
2007
65
42
Cancer vaccines: on the threshold of success
Expert Opinion on Emerging Drugs
2008
63
43
Emerging treatment for chronic migraine and refractory chronic migraine
Expert Opinion on Emerging Drugs
2012
63
44
Emerging human papillomavirus vaccines
Expert Opinion on Emerging Drugs
2012
62
45
Emerging drugs for neuropathic pain
Expert Opinion on Emerging Drugs
2014
62
46
Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases
Expert Opinion on Emerging Drugs
2003
59
47
Emerging potential of exosomes and noncoding microRNAs for the treatment of neurological injury/diseases
Expert Opinion on Emerging Drugs
2015
59
48
Potential therapeutic targets for neurokinin-1 receptor antagonists
Expert Opinion on Emerging Drugs
2004
58
49
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Expert Opinion on Emerging Drugs
2020
57
50
Emerging drug therapies for benign prostatic hyperplasia
Expert Opinion on Emerging Drugs
2006
56
site/software ©
exaly
; All materials licenced under
CC by-SA
.